Skip to main content

Bio-Rad Laboratories Inc. (BIO) Stock

Bio-Rad Laboratories Inc. Stock Details, Movements and Public Alerts

Stock Details

Bio-Rad Laboratories Inc. (BIO), a prominent company in the life sciences sector within the laboratory analytical instruments industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $246.53. Over the past 52 weeks, it has ranged between $211.43 and $387.99. This places the current price at 63.5% of its 52-week high and 16.6% above its 52-week low. Recent trading volume was recorded at 228,730. The International Securities Identification Number (ISIN) for this stock is US09061G1013.

Market Cap

$6.59B

52-Week High

$387.99

-36.46% from high

52-Week Low

$211.43

+16.60% from low

Avg Daily Volume

228,730

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

31.35

PEG Ratio

1.19

Reasonably valued

Price to Book

0.99

EV/EBITDA

-13.07

EPS (TTM)

-$75.70

Price to Sales

2.59

Beta

0.94

Less volatile than market

How is BIO valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is BIO's risk profile compared to the market?
With a beta of 0.94, Bio-Rad Laboratories Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 0.99 indicates the stock trades below its accounting value, which could signal value or distress.

Performance & Growth

Profit Margin

-85.20%

Operating Margin

9.72%

Return on Equity

-27.50%

Return on Assets

1.55%

Revenue Growth (YoY)

-4.20%

Earnings Growth (YoY)

-83.00%

How profitable and efficient is BIO's business model?
Bio-Rad Laboratories Inc. achieves a profit margin of -85.20%, meaning it retains $-85.20 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 9.72% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -27.50% and ROA at 1.55%, the company achieves moderate returns on invested capital.
What are BIO's recent growth trends?
Bio-Rad Laboratories Inc.'s revenue declined by 4.20% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 83.00% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against LABORATORY ANALYTICAL INSTRUMENTS industry averages for proper context.

Company Size & Market

Shares Outstanding

22.14M

Book Value/Share

$241.72

Asset Type

Common Stock

What is BIO's market capitalization and position?
Bio-Rad Laboratories Inc. has a market capitalization of $6.59B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 22.14M shares outstanding, the company's ownership is relatively concentrated. As a participant in the LABORATORY ANALYTICAL INSTRUMENTS industry, it competes with other firms in this sector.
How does BIO's price compare to its book value?
Bio-Rad Laboratories Inc.'s book value per share is $241.72, while the current stock price is $246.53, resulting in a price-to-book (P/B) ratio of 1.02. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$315.33

27.91% upside potential

Analyst Recommendations

Strong Buy

2

Buy

2

Hold

2

Sell

0

Strong Sell

0

How reliable are analyst predictions for BIO?
6 analysts cover BIO with 67% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $315.33 implies 27.9% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on BIO?
Current analyst recommendations:2 Strong Buy, 2 Buy, 2 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 04:39 AM

Technical Indicators

What does BIO's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret BIO's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for BIO and get notified when the price changes.

Stay Ahead of the Market with Bio-Rad Laboratories Inc. Alerts

Set up price alerts for Bio-Rad Laboratories Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.